GlassScriptPhysician profile
Eboni Charde' Farmer
NPI 1891447314
$9,651.85
in general payments reported to CMS, 2019-2025
46 companies · $605 in 2025
The $605 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,770 · 2023: $3,443 · 2024: $1,835 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,817 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,817.29 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,016.67 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $950.32 | 2022-2025 | |
| Novo Nordisk INC | $863.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $853.48 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $672.54 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $630.66 | 2022-2024 | |
| Astellas Pharma US INC | $528.99 | 2022-2024 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $430.48 | 2022-2024 | Nexletol |
| Amgen INC. | $383.78 | 2022-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.19 | 2022-2024 | Jardiance, Synjardy, Spiriva |
| Merck Sharp & Dohme LLC | $284.17 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Pfizer INC. | $273.76 | 2022-2024 | |
| Insulet Corporation | $262.06 | 2022-2024 | Omnipod |
| Novartis Pharmaceuticals Corporation | $260.67 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $150.15 | 2023-2024 | Gemtesa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eboni Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.